- $1.88bn
- $1.85bn
- $17.20m
- 50
- 20
- 66
- 42
Annual balance sheet for Mesoblast, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 136 | 60 | 70.9 | 62.6 | 161 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.84 | 4.4 | 7 | 3.4 | 14.9 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 148 | 69.8 | 81.7 | 86.5 | 204 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 12.1 | 9.96 | 6.49 | 3.84 | 5.82 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 745 | 662 | 669 | 669 | 785 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 94.3 | 51.4 | 42 | 73.2 | 103 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 163 | 165 | 168 | 189 | 187 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 581 | 497 | 502 | 480 | 597 |
| Total Liabilities & Shareholders' Equity | 745 | 662 | 669 | 669 | 785 |
| Total Common Shares Outstanding |